Press release
Niemann Pick Disease Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies by DelveInsight
Niemann Pick Disease Pipeline
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
DelveInsight's Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Download the Sample PDF:
https://www.delveinsight.com/report-store/niemann-pick-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Niemann Pick Disease Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Niemann Pick Disease Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Niemann Pick Disease treatment.
• Niemann Pick Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Niemann Pick Disease Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Niemann Pick Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/report-store/niemann-pick-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Niemann Pick Disease Therapeutics Analysis
There are approx. 20+ key companies which are developing the therapies for Niemann-Pick-Disease. Currently, Orphazyme has its Niemann-Pick-Disease drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Niemann Pick Disease Market include:
• Orphazyme
• Cyclo Therapeutics
• Mandos LLC
• IntraBio
• E-scape Bio
• Scenic Biotech
• Synaptogenix
• Evox Therapeutics
• StrideBio
• SOM Biotech
• ENDECE
• Oraxion Therapeutics
• Polaryx Therapeutics
And many others
Niemann Pick Disease Therapies covered in the report include:
• Arimoclomol (Orphazyme)
• Trappsol Cyclo (Cyclo Therapeutics)
• VTS-270 (Mandos LLC)
• ESB1609 (E-scape Bio)
And many more
Request the Sample PDF to Get a more in-depth Assessment: https://www.delveinsight.com/sample-request/niemann-pick-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Niemann Pick Disease Current Treatment Patterns
4. Niemann Pick Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Niemann Pick Disease Late Stage Products (Phase-III)
7. Niemann Pick Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Niemann Pick Disease Discontinued Products
13. Niemann Pick Disease Product Profiles
14. Niemann Pick Disease Key Companies
15. Niemann Pick Disease Key Products
16. Dormant and Discontinued Products
17. Niemann Pick Disease Unmet Needs
18. Niemann Pick Disease Future Perspectives
19. Niemann Pick Disease Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at:
https://www.delveinsight.com/sample-request/niemann-pick-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/niemann-pick-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Niemann Pick Disease Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies by DelveInsight here
News-ID: 2719726 • Views: …
More Releases from DelveInsight Business Research
Alpha-1 Antitrypsin Deficiency Pipeline 2025: MOA and ROA Insights, Clinical Tri …
Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial…
Alopecia Areata Market Expected to Gain Momentum Through 2034, According to Delv …
The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.
DelveInsight's "Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United…
Acne Vulgaris Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acne Vulgaris pipeline constitutes 20+ key companies continuously working towards developing 22+ Acne Vulgaris treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acne Vulgaris Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Stargardt Disease Market Dynamics Indicate Upward Trajectory Through 2034, Repor …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
More Releases for Niemann
Niemann-Pick Disease Market Accelerating Research and Treatment Innovations Driv …
The global Niemann-Pick disease market is poised for substantial growth as advancements in genetic research, early diagnosis, and novel therapies gain momentum.
Introduction:
The global Niemann-Pick disease market is expected to grow significantly in the coming years due to rising research investments, the development of novel therapies, and the increasing recognition of this rare, inherited lysosomal storage disorder. Niemann-Pick disease, which affects lipid metabolism and leads to organ damage, has limited treatment…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
Niemann Pick Disease Market Size, Share, Trends, Growth & Forecast 2034
The Niemann-Pick Disease Market Is Set To Grow At An Estimated CAGR Of 7.5% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $2.5 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Niemann Pick Disease market goods. The market study excludes key regions that are accelerating marketization. This…
Targeting Lysosomal Storage Disorders: The Future of Niemann-Pick Disease Therap …
Niemann-Pick Market is making significant strides in the industry with its latest advancements and strategic expansions. As a leading player, Niemann-Pick Market continues to revolutionize the sector with cutting-edge solutions and a commitment to excellence. The company's recent initiatives have strengthened Niemann-Pick Disease Treatment Market position in the global market, driving growth and innovation. With a strong focus on customer satisfaction, Lysosomal Storage Disorder Market has introduced new products and…
Exploring the Global Frontier of Niemann-Pick C1 Like Protein 1
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:
Welcome to our comprehensive analysis of the Global Niemann-Pick C1 Like Protein 1 Market. In this blog, we delve into the market size, share, and the impact of COVID-19 on this industry from 2023 to 2031. Niemann-Pick C1 Like Protein 1 (NPC1L1) plays a crucial role in cholesterol absorption and is a target for pharmaceutical intervention to manage hypercholesterolemia and related conditions.
𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The market for NPC1L1 inhibitors has witnessed substantial…
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials Development and Co …
DelveInsight's, "Niemann-Pick-Disease Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Niemann-Pick-Disease pipeline landscape. It covers the Niemann-Pick-Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Niemann-Pick-Disease Pipeline Report
• DelveInsight's Niemann-Pick-Disease pipeline report…
